Key result
Statin therapy significantly improved pulmonary arterial pressure compared with placebo in patients with pulmonary hypertension, particularly in the subtype due to COPD.
Why the study?
PH lacks satisfactory therapeutic strategies, and the effects of statins across different clinical types of PH have not been conclusive.
Does statin therapy reduce pulmonary arterial pressure in patients with pulmonary hypertension?
Meta-Analysis (n=657)
Does statin therapy reduce pulmonary arterial pressure in patients with pulmonary hypertension?
Statin therapy may safely reduce pulmonary arterial pressure in patients with pulmonary hypertension, particularly in those with PH secondary to COPD.
Answers are grounded in this paper and cite their sources.
May support adjunctive statins to lower pulmonary pressure in PH, especially COPD-related; extends meta-analytic evidence for targeted trials.
BACKGROUND: Pulmonary hypertension (PH) is a multi-causal disease and no satisfactory therapeutic strategies for it. Statins have been suggested as potential drugs in PH, whose effects in different clinic types of PH have not been conclusive. In this study, we included randomized controlled clinical trials (RCTs) evaluating the efficacy and safety of statins therapy in PH. METHODS: We searched databases including Medline, Embase, Cochrane, PubMed and Web of science, with time up to January 1, 2019. With 95% confidence interval (CI), weighted mean difference (WMD) or standardized mean difference (SMD) was pooled and calculated in a random or fixed effect model according to I2 statistic. RESULTS: A total of nine RCTs with 657 patients were included. Four types of statins (atorvastatin, pravastatin, rosuvastatin and simvastatin) were used at different doses (10-80 mg daily) for up to 6 months. In the pooled-data analysis, compared with placebo, there were significant improvements in pulmonary arterial pressure (PAP), in addition to low-density lipoprotein (LDL) in patients treated with statins, but not in 6-minute walking distance (6MWD), cardiac index (CDI). No more adverse events and all-cause mortality were revealed. Subgroup analysis indicated that statins could decrease PAP in the subtype of PH due to chronic obstructive pulmonary disease (COPD), but not pulmonary arterial hypertension (PAH). CONCLUSIONS: This study indicates that statins can efficiently and safely reduce PAP in PH, especially in the subtype due to COPD. Further RCTs are needed to focus on the efficacy and safety of statin therapy in different subtypes of PH.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) conducted a meta-analysis in Pulmonary hypertension (n=657). Statin therapy vs. Placebo was evaluated on Pulmonary arterial pressure (PAP). Statin therapy significantly improved pulmonary arterial pressure compared with placebo in patients with pulmonary hypertension, particularly in the subtype due to COPD.
Synapse has enriched 10 related papers. Consider them for comparative context: